SLC5A2 and type 2 diabetes mellitus: More recently, with multiple trials such as EMPEROR-Reduced (49), EMPEROR-Preserved (50), DAPA-HF (51), and DAPA-CKD (52), even in the absence of T2DM, SGLT2 inhibition benefited patients with chronic kidney disease and patients with heart failure (with either reduced or preserved ejection fraction).